S&P 500
(0.12%) 5 254.55 points
Dow J
(0.05%) 39 779 points
Nasdaq
(0.03%) 16 404 points
Oil
(1.65%) $82.69
Gas
(0.58%) $1.728
Gold
(0.98%) $2 234.40
Silver
(0.65%) $24.91
Platinum
(1.37%) $922.15
USD/EUR
(0.28%) $0.926
USD/NOK
(0.71%) $10.84
USD/GBP
(0.08%) $0.792
USD/RUB
(0.22%) $92.64

Realtime updates for Catalyst Pharmaceuticals [CPRX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
83.33%
return 4.42%
SELL
33.33%
return 3.66%
Last Updated28 Mar 2024 @ 11:53

-0.37% $ 16.21

BUY 61725 min ago

@ $13.37

Issued: 14 Feb 2024 @ 14:08


Return: 21.29%


Previous signal: Feb 13 - 10:35


Previous signal: Sell


Return: 0.00 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 11:53):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States...

Stats
Today's Volume 212 449
Average Volume 1.51M
Market Cap 1.91B
EPS $0 ( 2024-03-20 )
Next earnings date ( $0.360 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 25.73
ATR14 $0.0180 (0.11%)
Insider Trading
Date Person Action Amount type
2024-02-15 Del Carmen Jeffrey Sell 10 667 Restricted Stock Units
2024-02-15 Del Carmen Jeffrey Buy 10 667 Common stock, par value $0.001 per share
2024-02-15 Del Carmen Jeffrey Sell 3 125 Common stock, par value $0.001 per share
2024-02-15 Daly Richard J Sell 4 000 Restricted Stock Units
2024-02-15 Daly Richard J Buy 4 000 Common stock, par value $0.001 per share
INSIDER POWER
39.33
Last 100 transactions
Buy: 3 305 962 | Sell: 1 428 545

Volume Correlation

Long: -0.03 (neutral)
Short: -0.05 (neutral)
Signal:(51.879) Neutral

Catalyst Pharmaceuticals Correlation

10 Most Positive Correlations
PMTS0.897
KPTI0.88
AVID0.873
PRAA0.854
FCCO0.852
BNIXU0.849
PINC0.848
KTCC0.844
PARA0.843
DTEA0.838
10 Most Negative Correlations
CVGI-0.927
CRSP-0.915
NNOX-0.915
POWL-0.914
ADMS-0.914
FTDR-0.912
MDXG-0.912
FLGC-0.905
CNCE-0.905
RESN-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Catalyst Pharmaceuticals Correlation - Currency/Commodity

The country flag -0.16
( neutral )
The country flag 0.23
( neutral )
The country flag 0.00
( neutral )
The country flag 0.21
( neutral )
The country flag -0.63
( weak negative )
The country flag 0.04
( neutral )

Catalyst Pharmaceuticals Financials

Annual 2023
Revenue: $398.20M
Gross Profit: $313.67M (78.77 %)
EPS: $0.670
Q4 2023
Revenue: $110.57M
Gross Profit: $85.70M (77.51 %)
EPS: $0.330
Q3 2023
Revenue: $102.69M
Gross Profit: $88.52M (86.20 %)
EPS: $-0.290
Q2 2023
Revenue: $99.58M
Gross Profit: $87.54M (87.90 %)
EPS: $0.360

Financial Reports:

No articles found.

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators